We recently published a list of 10 Stocks Insiders Are Buying This Year. In this article, we are going to take a look at where Ibio, Inc. (NYSEAMERICAN:IBIO) stands against other stocks that insiders are buying this year.
Even though this is just the beginning of the year, we thought it might be interesting to see what stocks have attracted the most attention from insiders. Why? Sometimes, when executives or insiders acquire shares early in the year, it could mean that they expect strong financial results or positive company developments.
On the other hand, insiders sometimes sell shares at the beginning of the year for tax reasons. For example, they can sell shares to harvest tax loss or to balance out gains/losses from the previous year.
Both insider selling and buying can be driven by various motives, however, it’s important to consider these moves within the broader context of the company’s fundamentals, industry trends, and overall market conditions. That’s why due diligence before any investment is of the utmost importance. However, insider trading activity in combination with other relevant determinants can offer valuable insights into a company’s capabilities, helping investors make more informed investment decisions.
To identify the 10 stocks insiders are buying this year we used Insider Monkey’s insider trading stock screener and looked for stocks with at least five insiders buying since the beginning of the year. With each stock, we note the number of insiders who recently bought shares.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A biotechnologist in a lab wearing an apron and safety glasses, working on a biopharmaceutical process.
Ibio, Inc. (NYSEAMERICAN:IBIO)
Number of Insiders Buying: 7
Ibio, Inc. (NYSEAMERICAN:IBIO) is a biotech company focused on using AI and advanced computational biology to develop and design next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer, and other hard-to-treat diseases. The company combines proprietary 3D modeling with innovative drug discovery platforms to create a pipeline of new antibody treatments to address various unmet needs.
For the second quarter ended Dec. 31, 2024, Ibio reported revenue of $200,000. Net loss amounted to $4.36 million, which compares to net loss of $4.49 million in the same period last year.
On January 7, Ibio (NYSEAMERICAN:IBIO), in collaboration with AstralBio Inc., announced the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity using iBio’s patented Machine-Learning Antibody Engine.
Three days after the announcement, on January 10, seven insiders bought a total of around $654,995 worth of shares at a price of $2.72 per share. Among these insiders is the company’s chief financial officer, Felipe Duran, who acquired 9,191 shares worth nearly $25,000, increasing his holdings to 11,139 shares. It is possible that the management has a strong confidence in the development of an antibody that inhibits the function of Activin E, and therefore they decided to increase their holding and invest in the company.
Based on data from TipRanks, one Wall Street analyst has a Buy rating on the stock and a 12-month price forecast of $6. Moreover, three analysts have an average “Strong Buy” rating on Ibio stock, with a price target of $4.87, representing an increase of 41.98% from the latest price, reveals data from StockAnalysis.
As of February 14, 2025, IBIO has a market capitalization of approximately $33.87 million and an average trading volume of 340,448 shares. The stock is now trading at $3.43, having gained 40.00% year-to-date. Over the past 12 months, Ibio’s shares gained 172.22%.
Overall, IBIO ranks 7th on our list of stocks that insiders are buying this year. While we acknowledge the potential of IBIO, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBIO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
